Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Urovant Sciences Ltd.    UROV   BMG9381B1081

UROVANT SCIENCES LTD.

(UROV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2020 05/19/2020 05/20/2020 05/21/2020 05/22/2020 Date
8.78(c) 8.64(c) 8.75(c) 8.68(c) 8.75(c) Last
73 134 47 635 33 490 49 718 60 628 Volume
+2.09% -1.59% +1.27% -0.80% +0.81% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -134 M - -
Net Debt 2020 - - -
P/E ratio 2020 -2,00x
Yield 2020 -
Sales 2021 11,4 M - -
Net income 2021 -184 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,66x
Yield 2021 -
Capitalization 267 M 267 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 23,5x
Nbr of Employees 39
Free-Float 14,8%
More Financials
Company
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for urologic conditions. Its product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist. is focused on evaluating vibegron in its over 1,400 patients, pivotal phase-3 clinical trial for the treatment of overactive bladder (OAB). The Company’s subsidiaries... 
More about the company
Surperformance© ratings of Urovant Sciences Ltd.
Trading Rating : Investor Rating : -
More Ratings
Latest news on UROVANT SCIENCES LTD.
05/14UROVANT SCIENCES : Presents Positive Clinical Efficacy & Safety Data on Lead Dru..
BU
03/23UROVANT : Sciences Appoints James Robinson as President and Chief Executive Offi..
BU
03/05UROVANT SCIENCES : Announces U.S. FDA Acceptance of New Drug Application for Vib..
BU
03/02UROVANT SCIENCES : Announces Publication of Phase 3 EMPOWUR Trial Results in the..
BU
02/25UROVANT SCIENCES : to Present at Cowen and Company's 40th Annual Health Care Con..
BU
02/13UROVANT SCIENCES : Reports 2019 Third Fiscal Quarter Financial Results
BU
02/06UROVANT SCIENCES : to Report 2019 Third Fiscal Quarter Financial Results
BU
02/04UROVANT SCIENCES : Announces Publication of Results from Phase 1 Clinical Trials..
BU
01/17UROVANT SCIENCES : to Ring the Nasdaq Stock Market Opening Bell
BU
01/08UROVANT SCIENCES : to Present at the 38th Annual J.P. Morgan Healthcare Conferen..
BU
2019UROVANT SCIENCES : Announces Submission of New Drug Application for Vibegron for..
BU
2019UROVANT SCIENCES : Enters into $300 Million Term Loan Agreement with Sumitomo Da..
BU
2019UROVANT SCIENCES : Majority Shareholder, Roivant Sciences, and Sumitomo Dainippo..
BU
2019UROVANT SCIENCES : Initiates Patient Enrollment in Phase 2a Study of URO-902
BU
2019UROVANT SCIENCES : Reports 2019 Second Fiscal Quarter Financial Results
BU
More news
News in other languages on UROVANT SCIENCES LTD.

- No features available -

More news
Chart UROVANT SCIENCES LTD.
Duration : Period :
Urovant Sciences Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UROVANT SCIENCES LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 25,25 $
Last Close Price 8,75 $
Spread / Highest target 277%
Spread / Average Target 189%
Spread / Lowest Target 117%
EPS Revisions
Managers
NameTitle
James A. Robinson President, Chief Executive Officer & Director
Myrtle S. Potter Chairman
Ajay Bansal Chief Financial Officer & SVP-Business Development
Cornelia Haag-Molkenteller Chief Medical Officer
Sef P. Kurstjens Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
UROVANT SCIENCES LTD.-43.58%267
GILEAD SCIENCES12.87%91 996
VERTEX PHARMACEUTICALS30.15%73 883
REGENERON PHARMACEUTICALS51.78%63 465
WUXI APPTEC CO., LTD.14.69%24 438
GENMAB A/S36.89%19 339